Brief: Ascentage Pharma Group International Says APG-115 And APG-1252 Granted Orphan Drug Designation By US FDA
09/10/2020 02:05
Oct 9 (Reuters) - Ascentage Pharma Group International
6855.HK :
* APG-115 AND APG-1252 GRANTED ORPHAN DRUG DESIGNATION BY US
FDA
* DRUGS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA AND
SMALL-CELL
LUNG CANCER, RESPECTIVELY
Source text for Eikon: ID:nHKS9wbVKp
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up